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ABSTRACT 
Mitogen-activated protein kinases (MAPKs) are the main regulators of cellular proliferation, 
growth, and survival in physiologicalor pathological conditions. Aberrant MAPK signaling 
plays a pivotal role in carcinogenesis, which leads to development andprogression of human 
cancer. Dual-specificity phosphatase 6 (DUSP6), a member of the MAPK phosphatase 
family, interacts withspecifically targeted extracellular signal-regulated kinase 1/2 via 
negative feedback regulation in the MAPK pathway of mammaliancells. This phosphatase 
functions in a dual manner, pro-oncogenic or tumor-suppressive, depending on the type of 
cancer. Todate, the tumor-suppressive role of DUSP6 has been demonstrated in pancreatic 
cancer, non-small cell lung cancer, esophagealsquamous cell and nasopharyngeal carcinoma, 
and ovarian cancer. Its pro-oncogenic role has been observed in humanglioblastoma, thyroid 
carcinoma, breast cancer, and acute myeloid carcinoma. Both roles of DUSP6 have been 
documented inmalignant melanoma depending on the histological subtype of the cancer. 
Loss- or gain-of-function effects of DUSP6 in thesecancers highlights the significance of this 
phosphatase in carcinogenesis. Development of methods that use the DUSP6 gene as 
atherapeutic target for cancer treatment or as a prognostic factor for diagnosis and evaluation 
of cancer treatment outcome hasgreat potential. This review focuses on molecular 
characteristics of the DUSP6 gene and its role in cancers in the purview ofdevelopment, 
progression, and cancer treatment outcome. 
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